CORRECTION article

Front. Immunol., 13 December 2022

Sec. Multiple Sclerosis and Neuroimmunology

Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.1095038

Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands

  • FP

    Fay Probert 1*

  • TY

    Tianrong Yeo 2,3,4

  • YZ

    Yifan Zhou 2,5,6

  • MS

    Megan Sealey 2

  • SA

    Siddharth Arora 7

  • JP

    Jacqueline Palace 8

  • TD

    Timothy D. W. Claridge 1

  • RH

    Rainer Hillenbrand 9

  • JO

    Johanna Oechtering 10

  • JK

    Jens Kuhle 10

  • DL

    David Leppert 10

  • DC

    Daniel C. Anthony 2*

  • 1. Department of Chemistry, University of Oxford, Oxford, United Kingdom

  • 2. Department of Pharmacology, University of Oxford, Oxford, United Kingdom

  • 3. Department of Neurology, National Neuroscience Institute, Singapore, Singapore

  • 4. Duke-National University of Singapore (NUS) Medical School, Singapore, Singapore

  • 5. Translational Stem Cell Biology Branch, National Institutes of Health, Bethesda, MD, United States

  • 6. Wellcome Medical Research Council (MRC) Trust Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom

  • 7. Department of Mathematics, University of Oxford, Oxford, United Kingdom

  • 8. Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom

  • 9. Biomarker Development, Novartis Pharma AG, Basel, Switzerland

  • 10. Neurologic Clinic and Policlinic, Multiple Sclerosis (MS) Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland

This article is a correction to:

  1. Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands

    1. Read original article

A Corrigendum on Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands by Probert F, Yeo T, Zhou Y, Sealey M, Arora S, Palace J, Claridge TDW, Hillenbrand R, Oechtering J, Kuhle J, Leppert D and Anthony DC (2022). Front. Immunol. 12:811351. doi: 10.3389/fimmu.2021.811351

In the published article, there was an error in the Data Availability statement which was: "The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material". The correct Data Availability statement appears below.

Statements

Data availability statement

The datasets presented in this article are not readily available because they contain identifiable information from human subjects that cannot be shared in open access repositories for legal reasons. Anonymized data will be shared upon request from any qualified investigator. Requests should be directed to the corresponding authors.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

diagnosis, metabolomics (OMICS), multiple sclerosis (MS), proteomics, oligoclonal band, biomarker

Citation

Probert F, Yeo T, Zhou Y, Sealey M, Arora S, Palace J, Claridge TDW, Hillenbrand R, Oechtering J, Kuhle J, Leppert D and Anthony DC (2022) Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands. Front. Immunol. 13:1095038. doi: 10.3389/fimmu.2022.1095038

Received

10 November 2022

Accepted

11 November 2022

Published

13 December 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

© 2022 Probert, Yeo, Zhou, Sealey, Arora, Palace, Claridge, Hillenbrand, Oechtering, Kuhle, Leppert and Anthony.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Daniel C. Anthony, ; Fay Probert,

This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Immunology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Share on WeChat

Scan with WeChat to share this article

Article metrics